A Novel Classification of Heart Failure Derived from the Nationwide JROADHF Cohort Using Unsupervised Machine Learning
Abstract Body (Do not enter title and authors here): Introduction/Background Heart failure (HF) care is still steered almost solely by left-ventricular ejection fraction (LVEF), yet outcomes remain sub-optimal, suggesting that the HFrEF/HFmrEF/HFpEF scheme is too crude for precision therapy. Research Question/Hypothesis We hypothesised that unsupervised machine learning (ML) applied to routinely collected variables could yield a more informative HF stratification than the conventional LVEF-based framework. Goals/Aims To develop an ML-derived multidimensional HF classification, test its prognostic performance, and compare it with existing LVEF categories. Methods/Approach We analysed 13,238 patients in the nationwide JROAD-HF registry in Japan. Forty-six clinical, laboratory, and echocardiographic variables entered a latent-class model; the cohort was randomly split 1:1 into discovery and internal-validation sets to assess robustness. (Figure 1) Clinical endpoint defined as a composite of 5-year cardiovascular death and heart failure readmission. Results The model identified three phenogroups by minimum Bayesian Information Criteria. Phenogroup 1 “Advanced Low-Output HF” (predominantly male, age 73.6 ± 12 years) showed severe systolic dysfunction (LVEF 35.5 %), renal impairment, and heavy burdens of ischemic heart disease (52 %) and cardiomyopathy (29%). Phenogroup 2 “Early Afterload-Mismatch HF” (predominantly male, age 68.8 ± 12 years) was the youngest, markedly hypertensive, with intermediate LVEF (41.9%) and diverse etiologies. Phenogroup 3 “Elderly HFpEF-like HF” (predominantly female, age 84.5 ± 7 years) was lean and anemic, with preserved LVEF 53.5%, atrial fibrillation (45%), and valvular disease (42%). The four most discriminative variables were age, total bilirubin, LV diastolic diameter, and serum hemoglobin rather than LVEF and yielded an adjusted Rand index of 0.94 in the validation set, indicating excellent reproducibility. Five-year Kaplan–Meier curves showed the lowest mortality in Phenogroup 2 and the highest in Phenogroup 1 (log-rank p < 0.001), whereas LVEF categories showed no significant separation (p = 0.267) (Figure 2 A and B). Conclusions ML-driven phenomapping of routine hospital data delineated three distinct HF groups that outperformed the traditional LVEF classification in prognostic discrimination.
Kyodo, Atsushi
( Nara Medical University
, Kashihara
, Japan
)
Tsutsui, Hiroyuki
( Kyushu University
, Fukuoka
, Japan
)
Hikoso, Shungo
( Nara Medical University
, Kashihara
, Japan
)
Nakada, Yasuki
( Nara Medical University
, Kashihara
, Japan
)
Nogi, Kazutaka
( Nara Medical University
, Kashihara
, Japan
)
Ishihara, Satomi
( Nara Medical University
, Nara-ken Kashihara-shi
, Japan
)
Ueda, Tomoya
( Nara Medical University
, Kashihara
, Japan
)
Tohyama, Takeshi
( Massachusetts Institute of Technology
, Cambride
, Massachusetts
, United States
)
Enzan, Nobuyuki
( The Broad Institute
, Cambridge
, Massachusetts
, United States
)
Matsushima, Shouji
( Kyushu University Hospital
, Fukuoka
, Japan
)
Ide, Tomomi
( KYUSHU UNIVERSITY
, Fukuoka
, Japan
)
Author Disclosures:
Atsushi Kyodo:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Japan Society for the Promotion of Science:Active (exists now)
| Hiroyuki Tsutsui:DO have relevant financial relationships
;
Advisor:Ono Pharmaceutical Co., Ltd., Bayer Yakuhin, Ltd., Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd:Active (exists now)
; Speaker:AstraZeneca KK, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., TSUMURA & CO, Terumo Corp, Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Novo Nordisk Pharma Ltd., Bayer Yakuhin, Ltd., Pfizer Japan Inc., Viatris Inc.:Active (exists now)
| Shungo Hikoso:DO have relevant financial relationships
;
Advisor:Kowa Company, Ltd.:Past (completed)
; Researcher:The Ministry of Health Labour and Welfare:Active (exists now)
; Researcher:The Ministry of Education, Culture, Sports, Science and Technology:Active (exists now)
; Speaker:Kowa Company, Ltd.:Active (exists now)
; Speaker:Bristol-Myers Squibb K.K.:Active (exists now)
; Speaker:Bayer Yakuhin Ltd.:Past (completed)
; Speaker:Novartis Pharma K.K.:Active (exists now)
; Speaker:AstraZeneca K.K.:Active (exists now)
; Speaker:MSD K.K.:Active (exists now)
; Speaker:Nippon Boehringer Ingelheim Co., Ltd.:Active (exists now)
; Speaker:Daiichi Sankyo Co., Ltd:Past (completed)
; Research Funding (PI or named investigator):Mochida Pharmaceutical Co., Ltd.:Past (completed)
; Advisor:Bayer Yakuhin Ltd.:Past (completed)
; Advisor:Nippon Boehringer Ingelheim Co., Ltd.:Past (completed)
; Advisor:Eli Lilly Japan K.K.:Past (completed)
| Yasuki Nakada:DO NOT have relevant financial relationships
| kazutaka nogi:No Answer
| Satomi Ishihara:No Answer
| Tomoya Ueda:No Answer
| Takeshi Tohyama:DO NOT have relevant financial relationships
| Nobuyuki Enzan:DO NOT have relevant financial relationships
| Shouji Matsushima:DO NOT have relevant financial relationships
| Tomomi Ide:No Answer